Head to Head Comparison: Actinium Pharmaceuticals (NYSE:ATNM) vs. NanoViricides (NYSE:NNVC)

Actinium Pharmaceuticals (NYSE:ATNM) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Valuation & Earnings

This table compares Actinium Pharmaceuticals and NanoViricides”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90,000.00	345.13	-$48.82 million	($0.75)	-1.32
NanoViricides	N/A	N/A	-$8.29 million	($0.43)	-3.19

NanoViricides has lower revenue, but higher earnings than Actinium Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Actinium Pharmaceuticals and NanoViricides, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	0	1	0	3.00
NanoViricides	0	0	1	0	3.00

Actinium Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 405.05%. Given Actinium Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than NanoViricides.

Institutional and Insider Ownership

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Actinium Pharmaceuticals and NanoViricides’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
NanoViricides	N/A	-87.90%	-78.69%

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

About NanoViricides

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.